Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Unresectable intrahepatic cholangiocarcinoma (ICC) with Concomitant Systemic Gemcitabine and Cisplatin (Gem-Cis)

The purpose of this study is to find out if the combination of trans-arterial chemoembolization (LC BEAD) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.

Inclusion Criteria:
• Patients with at least one measurable liver tumor, with size > 1cm (modified RECIST criteria)
• Patients with liver-dominant disease defined as ≥80% tumor burden confined to the liver

Exclusion Criteria:
• Patient eligible for curative treatment (i.e. resection or tumor ablation).
• Active bacterial, viral or fungal infection within 72 hours of study entry
Phase II
Paul Hansen, M.D.
University of Lousiville
Mary Mccormick
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Newberg
  • Oncology and Hematology Care Southeast
  • Oncology and Hematology Care Westside
  • Providence Milwaukie Hospital
  • Providence St. Vincent Medical Center